打开APP

安斯泰来降压药Micamlo获日本MHLW批准

  1. Micamlo
  2. 安斯泰来

来源:生物谷 2012-12-24 16:05

2012年12月24日讯 /生物谷BIOON/ --安斯泰来(Astellas)宣布,降压药Micamlo片获日本卫生劳动福利部(MHLW)批准。该药是首个高剂量血管紧张素II-1型受体阻断剂(ARB)替米沙坦(telmisartan,80mg)和长效钙通道阻滞剂(CCB)氨氯地平(amlodipine,5mg)的组合药物,具有强大的降压作用,持续时间可达24h。

2012年12月24日讯 /生物谷BIOON/ --安斯泰来(Astellas)宣布,降压药Micamlo片获日本卫生劳动福利部(MHLW)批准。该药是首个高剂量血管紧张素II-1型受体阻断剂(ARB)替米沙坦(telmisartan,80mg)和长效钙通道阻滞剂(CCB)氨氯地平(amlodipine,5mg)的组合药物,具有强大的降压作用,持续时间可达24h。(生物谷bioon.com)

英文原文:

Tokyo, Japan, December 21, 2012 - Nippon Boehringer Ingelheim Co., Ltd. (Headquarters: Shinagawa-ku, Tokyo; President: Yoshiaki Aono; hereinafter "NBI") and Astellas Pharma Inc. (Tokyo:4503, Headquarters: Chuo-ku, Tokyo; President & CEO: Yoshihiko Hatanaka; hereinafter "Astellas") today announced that they have obtained approval for manufacturing and marketing of "Micamlo® Combination Tablets BP," a combination drug of telmisartan 80 mg, a long-acting angiotensin II type 1 (AT1) receptor blocker (ARB), and amlodipine 5 mg, a long-acting calcium channel blocker (CCB).

"Micamlo® Combination Tablets BP" is the first combination drug of high dose ARB and CCB in Japan. While "Micamlo® Combination Tablets AP" is a combination drug of telmisartan 40 mg and amlodipine 5 mg, the amount of telmisartan in "Micamlo® Combination Tablets BP" has been increased to 80 mg. This is, therefore, expected to maintain a more potent antihypertensive effect for 24 hours compared with that of the conventional ARB/CCB combination drug.

"Micamlo® Combination Tablets BP" can be, in principle, administered when blood pressure is not adequately controlled by any one of treatments with "telmisartan 80 mg in combination with amlodipine 5 mg," "telmisartan 80 mg," "telmisartan 40 mg in combination with amlodipine 5 mg," or "Micamlo® Combination Tablets AP."

In a Phase III clinical study of "Micamlo® Combination Tablets BP" conducted in Japan, 173 patients analysed with essential hypertension not having achieved a blood pressure control target (diastolic blood pressure).

版权声明 本网站所有注明“来源:生物谷”或“来源:bioon”的文字、图片和音视频资料,版权均属于生物谷网站所有。非经授权,任何媒体、网站或个人不得转载,否则将追究法律责任。取得书面授权转载时,须注明“来源:生物谷”。其它来源的文章系转载文章,本网所有转载文章系出于传递更多信息之目的,转载内容不代表本站立场。不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。

87%用户都在用生物谷APP 随时阅读、评论、分享交流 请扫描二维码下载->